Dunn Edmund 4

What Happened

• Edmund Dunn, Principal Accounting Officer of Monte Rosa Therapeutics (GLUE), exercised options and sold shares. On Feb 27, 2026 he exercised 25,164 shares at $13.41 (cost $337,449) and concurrently sold those 25,164 shares at a weighted average price of $18.10 for proceeds of $455,506. On Mar 2, 2026 he exercised 536 shares at $13.41 (cost $7,188) and sold the 536 shares at $17.50 for proceeds of $9,380. Total shares exercised = 25,700; total cash proceeds from sales ≈ $464,886.
• These transactions are effectively option exercises followed by immediate sale (i.e., the exercised shares were sold rather than retained), which results in net cash proceeds after payment of the exercise costs.

Key Details

• Transaction dates and prices:
  • 2026-02-27: Exercised 25,164 options at $13.41 (acquisition cost $337,449) and sold 25,164 shares at weighted avg $18.10 (proceeds $455,506). Sale prices ranged $18.06–$18.22 (footnote).
  • 2026-03-02: Exercised 536 options at $13.41 (cost $7,188) and sold 536 shares at $17.50 (proceeds $9,380).
• Option status: The option exercised is fully vested (footnote F2).
• Footnote: The $18.10 sale price is a weighted average; individual sales ranged $18.06–$18.22 (footnote F1). The filing offers to provide per-price detail on request.
• Shares owned after the transactions: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed on 2026-03-02 for transactions on 2026-02-27 and 2026-03-02; this appears timely under the two-business-day reporting rule.

Context

• These entries show option exercises immediately followed by sales (often called a cashless or sell-to-cover pattern). That means the insider realized cash proceeds rather than increasing or holding a long-term equity stake.
• Reporting person is an officer (Principal Accounting Officer); no 10% owner status is indicated in the filing excerpt.
• As always, insider sales can be routine (tax or liquidity reasons); they are factual disclosures and do not by themselves indicate company performance or insider sentiment.